INT339386

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2010
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 1.91
Pain Relevance 0.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apob) transport (Apob) extracellular space (Apob)
extracellular region (Apob) endoplasmic reticulum (Apob) enzyme binding (Apob)
Anatomy Link Frequency
plasma 2
Apob (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cytokine 63 91.76 High High
Inflammation 58 74.48 Quite High
Inflammatory response 21 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
Bile 2 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Angina 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 23 100.00 Very High Very High Very High
Chronic Disease 3 96.96 Very High Very High Very High
Hypercholesterolemia 22 96.22 Very High Very High Very High
Obesity 121 89.92 High High
Hyperlipoproteinemia Type Ii 27 88.20 High High
Hyperlipidemia 2 76.80 Quite High
INFLAMMATION 79 74.48 Quite High
Syndrome 15 72.16 Quite High
Erythema 1 37.68 Quite Low
Influenza Virus Infection 1 34.88 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The overtrained and recovered groups showed diminished apoB protein expression (p < 0.05) compared with the control group.
Negative_regulation (diminished) of Gene_expression (expression) of apoB protein
1) Confidence 0.43 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2959201 Disease Relevance 0.30 Pain Relevance 0.09
Furthermore, increased plasma TAG was accompanied by reduced apoB protein expression in the liver, possibly inducing hepatic steatosis, leading the organism to chronic disease.
Spec (possibly) Negative_regulation (reduced) of Gene_expression (expression) of apoB protein in plasma associated with chronic disease
2) Confidence 0.43 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2959201 Disease Relevance 0.77 Pain Relevance 0.17
Figure 2 shows hepatic apoB (Figure 2a) and TLR-4 (Figure 2b) protein expression.
Negative_regulation (shows) of Gene_expression (expression) of apoB
3) Confidence 0.27 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2959201 Disease Relevance 0.30 Pain Relevance 0.09
Pijlman et al reported that only 21% of the patients with heterozygous hypercholesterolemia in the Netherlands achieved the treatment goal, which required new medical options to be combined with current treatments.53 Mipomersen, a second-generation antisense oligonucleotide, can inhibit the synthesis of apolipoprotein B-100, which is an essential component of all atherogenic lipoproteins such as LDL and has been used to lower cholesterol level in patients with hypercholesterolemia.54 In a multicenter, randomized, double-blind, placebo-controlled trial, Raal et al used mipomersen to treat patients with homozygous familial hypercholesterolemia older than 12 years who were already receiving maximum tolerated doses of lipid-lowering drugs.55 They injected 200 mg mipomersen subcutaneously every week for 26 weeks to a treatment group and compared them with those who received placebo.
Negative_regulation (inhibit) of Gene_expression (synthesis) of apolipoprotein B-100 associated with hyperlipoproteinemia type ii, disorder of lipid metabolism and hypercholesterolemia
4) Confidence 0.02 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004511 Disease Relevance 0.54 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox